Gender Disparity in Enrollment in Clinical Trials for Hairy Cell Leukemia Treatments in the Last 40 Years
ABSTRACT Background Hairy Cell Leukemia (HCL) is a B‐cell lymphoproliferative disorder that predominantly affects males, yet recent evidence suggests a notable gender participation gap in HCL clinical trials. This study aims to characterize that disparity and explore potential factors contributing t...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-06-01
|
| Series: | eJHaem |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/jha2.70065 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849419455584534528 |
|---|---|
| author | Oscar F. Borja‐Montes Anna Bode Tomas Escobar‐Gil Alejandro Toro‐Pedroza Narandranath Epperla Leslie A. Andritsos |
| author_facet | Oscar F. Borja‐Montes Anna Bode Tomas Escobar‐Gil Alejandro Toro‐Pedroza Narandranath Epperla Leslie A. Andritsos |
| author_sort | Oscar F. Borja‐Montes |
| collection | DOAJ |
| description | ABSTRACT Background Hairy Cell Leukemia (HCL) is a B‐cell lymphoproliferative disorder that predominantly affects males, yet recent evidence suggests a notable gender participation gap in HCL clinical trials. This study aims to characterize that disparity and explore potential factors contributing to the under‐enrollment of females. Methods In this descriptive, retrospective study, we searched EMBASE, PUBMED, Cochrane Central, and ClinicalTrials.gov from January 1983 to December 2023 for publications on clinical trials (CT) in HCL, descriptive statistical analysis of all the sociodemographic variables was performed. Results We analyzed 57 clinical trials totaling 4595 HCL patients, with 79.1% male and 20.9% female participants. The male‐to‐female ratio declined from 5.91 (1983–1993) to 4.19 (2014–2023). Although the gender gap narrowed over time, female participation slightly decreased to 19.2% in the most recent period (2014–2023). Conclusions Female enrollment in HCL clinical trials remains disproportionately low compared to incidence rates, underscoring the need to address underlying barriers to improve equity in clinical research and treatment outcomes. Trial Registration The authors have confirmed clinical trial registration is not needed for this submission. |
| format | Article |
| id | doaj-art-7604ca482ecc45db8743c77733f6112c |
| institution | Kabale University |
| issn | 2688-6146 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | eJHaem |
| spelling | doaj-art-7604ca482ecc45db8743c77733f6112c2025-08-20T03:32:04ZengWileyeJHaem2688-61462025-06-0163n/an/a10.1002/jha2.70065Gender Disparity in Enrollment in Clinical Trials for Hairy Cell Leukemia Treatments in the Last 40 YearsOscar F. Borja‐Montes0Anna Bode1Tomas Escobar‐Gil2Alejandro Toro‐Pedroza3Narandranath Epperla4Leslie A. Andritsos5Department of Internal Medicine University of New Mexico Albuquerque New Mexico USADepartment of Internal Medicine University of New Mexico Albuquerque New Mexico USADepartment of Internal Medicine University of New Mexico Albuquerque New Mexico USAFundación Valle Del Lili, ICESI University Cali ColombiaDivision of Hematology and Hematologic Malignancies Huntsman Cancer Institute, University of Utah Salt Lake USADepartment of Hematology University of New Mexico Albuquerque New Mexico USAABSTRACT Background Hairy Cell Leukemia (HCL) is a B‐cell lymphoproliferative disorder that predominantly affects males, yet recent evidence suggests a notable gender participation gap in HCL clinical trials. This study aims to characterize that disparity and explore potential factors contributing to the under‐enrollment of females. Methods In this descriptive, retrospective study, we searched EMBASE, PUBMED, Cochrane Central, and ClinicalTrials.gov from January 1983 to December 2023 for publications on clinical trials (CT) in HCL, descriptive statistical analysis of all the sociodemographic variables was performed. Results We analyzed 57 clinical trials totaling 4595 HCL patients, with 79.1% male and 20.9% female participants. The male‐to‐female ratio declined from 5.91 (1983–1993) to 4.19 (2014–2023). Although the gender gap narrowed over time, female participation slightly decreased to 19.2% in the most recent period (2014–2023). Conclusions Female enrollment in HCL clinical trials remains disproportionately low compared to incidence rates, underscoring the need to address underlying barriers to improve equity in clinical research and treatment outcomes. Trial Registration The authors have confirmed clinical trial registration is not needed for this submission.https://doi.org/10.1002/jha2.70065B‐lymphocytesclinical trialsGender disparityhairy cell leukemia |
| spellingShingle | Oscar F. Borja‐Montes Anna Bode Tomas Escobar‐Gil Alejandro Toro‐Pedroza Narandranath Epperla Leslie A. Andritsos Gender Disparity in Enrollment in Clinical Trials for Hairy Cell Leukemia Treatments in the Last 40 Years eJHaem B‐lymphocytes clinical trials Gender disparity hairy cell leukemia |
| title | Gender Disparity in Enrollment in Clinical Trials for Hairy Cell Leukemia Treatments in the Last 40 Years |
| title_full | Gender Disparity in Enrollment in Clinical Trials for Hairy Cell Leukemia Treatments in the Last 40 Years |
| title_fullStr | Gender Disparity in Enrollment in Clinical Trials for Hairy Cell Leukemia Treatments in the Last 40 Years |
| title_full_unstemmed | Gender Disparity in Enrollment in Clinical Trials for Hairy Cell Leukemia Treatments in the Last 40 Years |
| title_short | Gender Disparity in Enrollment in Clinical Trials for Hairy Cell Leukemia Treatments in the Last 40 Years |
| title_sort | gender disparity in enrollment in clinical trials for hairy cell leukemia treatments in the last 40 years |
| topic | B‐lymphocytes clinical trials Gender disparity hairy cell leukemia |
| url | https://doi.org/10.1002/jha2.70065 |
| work_keys_str_mv | AT oscarfborjamontes genderdisparityinenrollmentinclinicaltrialsforhairycellleukemiatreatmentsinthelast40years AT annabode genderdisparityinenrollmentinclinicaltrialsforhairycellleukemiatreatmentsinthelast40years AT tomasescobargil genderdisparityinenrollmentinclinicaltrialsforhairycellleukemiatreatmentsinthelast40years AT alejandrotoropedroza genderdisparityinenrollmentinclinicaltrialsforhairycellleukemiatreatmentsinthelast40years AT narandranathepperla genderdisparityinenrollmentinclinicaltrialsforhairycellleukemiatreatmentsinthelast40years AT leslieaandritsos genderdisparityinenrollmentinclinicaltrialsforhairycellleukemiatreatmentsinthelast40years |